The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment – Current and Future Tools

Por Bartsch, Rupert, Steger, Guenther G.
Publicado em 2009

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion

Por Steger, Guenther G., Bartsch, Rupert
Publicado em 2011

Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer

Por Steger, Guenther G., Bartsch, Rupert
Publicado em 2011

Trastuzumab in the management of early and advanced stage breast cancer

Por Bartsch, Rupert, Wenzel, Catharina, Steger, Guenther G
Publicado em 2007

Breast Cancer: Rank Ligand Inhibition

Por Bartsch, Rupert, Steger, Guenther G., Gnant, Michael, Ziebermayr, Reinhard
Publicado em 2010

Treatment of Bone Metastases in Patients with Advanced Breast Cancer

Por Gnant, Michael, Balic, Marija, Petru, Edgar, Raunik, Wolfgang, Singer, Christian F., Steger, Guenther G., Watzke, Ingeborg M., Brodowicz, Thomas
Publicado em 2012

Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer

Por Preusser, Matthias, Fülöp, Gerhard, Berghoff, Anna Sophie, Heinzl, Harald, Steger, Guenther G., Greil, Richard, Zielinski, Christoph C., Bartsch, Rupert
Publicado em 2012

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer

Por Gampenrieder, Simon P., Bartsch, Rupert, Matzneller, Peter, Pluschnig, Ursula, Dubsky, Peter, Gnant, Michael X., Zielinski, Christoph C., Steger, Guenther G.
Publicado em 2010

Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel

Por Bartsch, Rupert, Steger, Guenther G, Forstner, Birgit, Wenzel, Catharina, Pluschnig, Ursula, Rizovski, Blanka, Altorjai, Gabriela, Zielinski, Christoph C, Mader, Robert M
Publicado em 2007

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

Por Bartsch, Rupert, Wenzel, Catharina, Pluschnig, Ursula, Hussian, Dagmar, Sevelda, Ursula, Altorjai, Gabriela, Locker, Gottfried J, Mader, Robert, Zielinski, Christoph C, Steger, Guenther G
Publicado em 2006

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

Por Bartsch, Rupert, Wenzel, Catharina, Hussian, Dagmar, Pluschnig, Ursula, Sevelda, Ursula, Koestler, Wolfgang, Altorjai, Gabriela, Locker, Gottfried J, Mader, Robert, Zielinski, Christoph C, Steger, Guenther G
Publicado em 2006

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Por Bartsch, Rupert, De Vries, Catharina, Pluschnig, Ursula, Dubsky, Peter, Bago-Horvath, Zsuzsanna, Gampenrieder, Simon P, Rudas, Margaretha, Mader, Robert M, Rottenfusser, Andrea, Wiltschke, Christoph, Gnant, Michael, Zielinski, Christoph C, Steger, Guenther G
Publicado em 2009

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer

Por Bergen, Elisabeth, Berghoff, Anna S., Rudas, Margaretha, Dubsky, Peter, De Vries, Catharina, Sattlberger, Claudia, Mader, Robert M., Zagouri, Flora, Sparber, Cornelia, Fitzal, Florian, Gnant, Michael, Rottenfusser, Andrea, Zielinski, Christoph C., Preusser, Matthias, Steger, Guenther G., Bartsch, Rupert
Publicado no Breast Care (Basel) (2014)